Psychedelic Medicine and Science Roundup Graphic

Psychedelic Science and Medicine Roundup: March 21-March 26

Share on facebook
Share on twitter
Share on linkedin
Share on email

With each passing week, we are seeing more and more advances in psychedelic research from the scientific and medical fields. As the body of research continues to grow, Truffle Report has compiled a roundup of major medical and scientific news from March 21 to March 26 2021, making it easier for you to track these ongoing developments.

Lab Expansion Project in Nanaimo to Aid Magic Mushroom, Psychedelics Research

March 21 , 2021 Numinus Wellness Inc., based in British Columbia, is expected to add a 7,500-square-foot addition to its existing complex by the end of 2021. This expansion will strengthen the facility’s research capacity.

New Research Could Help Predict Acute Reactions to Psychedelic Drugs

March 22, 2021 – New research from Ohio State University has identified personality traits that have been associated with positive and negative experiences on psychedelics in previous studies. This information could help predict how future patients will respond to the drugs.

Psychedelic Joint Venture Between Mycotopia Therapies and Natural MedTech Brings Research and Drug Development to Test Active Ingredient In Psychedelics

March 22, 2021 – Mycotopia Therapies, (OTC Pink: TWGL) (the “Company”), a Florida based company focused on psychedelic therapies, announced this week it has created PsyBioMed – Australia and that they have entered into a letter of intent to jointly conduct clinical trials in Australia using psychedelics to treat mental illnesses. This partnership intends to obtain licences and permits to legally possess, supply, sell, and manufacture psychedelics in Australia.

See Also
MDMA Psychedelic Therapy MAPS Interview Image

UW–Madison Pioneers Master’s Program in Therapeutic Use of Psychoactive Drugs

March 23, 2021 – The University of Wisconsin–Madison School of Pharmacy will enroll students in their new online MS in Pharmaceutical Sciences: Psychoactive Pharmaceutical Investigation this fall. This is the first and only master’s program of its kind in the United States. 

XPhyto Therapeutics Diversifies Into Psychedelics With New Labs

March 25, 2021 – XPhyto Therapeutics, a Vancouver based corporation, is currently expanding into psychedelic medicines by launching XPhyto Laboratories. The company’s focus involves the formulation of psychedelic compounds into mood-improving and therapeutic pharmaceutical drugs. XPhyto’s psychedelic research is led by German psychedelic researcher Professor Raimar Löbenberg.

Can you experience #psilocybin withdrawal?

Chemical dependence isn't usually an issue with psychedelics, but it's important to examine your relationship with any substance, particularly one that is fast becoming a mental health fix.

Full article here:

"Scientists are designing new psychedelic-inspired drugs that don’t yet exist, which might have effects no one can yet describe."

Beckley Psytech leads a new project focused on addressing psychiatric and neurological conditions through the use of psychedelic medicines.

Introduced by Representative @PeterforMO, a new bill in Missouri proposes to significantly decrease penalties for possession of #psychedelics, #cannabis, and other controlled substances.

Full story here:

#missouri #missourinews #legal #statelaw

Covering psychedelics reform in 2022—and its rapidly growing bipartisan appeal—has been so interesting. Like:

“We don't need to lock up people because they ate some mushrooms” is something a GOP lawmaker in one of the most conservative state legislatures casually just told me.

Load More...

Related Articles

Scroll To Top